Advertisement

Adjuvant Endocrine Therapy

  • Rena Shah
  • Ruth M. O’ReganEmail author
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 173)

Abstract

The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects. Molecular profiling has allowed therapy to be tailored for an individual patient to some extent. However, further molecular studies are needed to individualize the choice and length of adjuvant hormone therapy. Ongoing studies are evaluating the role of additional targeted therapies, such as CDK4/6 inhibitors, to further improve outcome for patients with early-stage hormone receptor-positive breast cancer.

Keywords

Breast cancer Adjuvant Endocrine therapy Hormone therapy Tamoxifen Aromatase inhibitors Molecular profiling  

References

  1. 1.
    Albain KS et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology 11(1):55–65Google Scholar
  2. 2.
    Anonymous (2010) Pathologists’ guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Care (Basel) 5(3):185–187Google Scholar
  3. 3.
    Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B et al (2006) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757. Erratum in: N Engl J Med 2006 May 18, 354(20):2200Google Scholar
  4. 4.
    Buus R et al (2016) Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11)Google Scholar
  5. 5.
    Cardoso F et al (2016) MINDACT investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729CrossRefPubMedGoogle Scholar
  6. 6.
    Chia SK et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465–4472. Epub 2012 June 18Google Scholar
  7. 7.
    Coombes R et al (2004) Intergroup exemestane study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092CrossRefPubMedGoogle Scholar
  8. 8.
    Davies C et al (2013) Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Eggeman H et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137(2):465–470. Epub 2012 Dec 9Google Scholar
  10. 10.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717Google Scholar
  11. 11.
    Fisher B et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542CrossRefPubMedGoogle Scholar
  12. 12.
    Giordano S et al (2005) Adjuvant systemic therapy for male breast carcinoma. Cancer 104(11):2359CrossRefPubMedGoogle Scholar
  13. 13.
    Goss P et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802CrossRefPubMedGoogle Scholar
  14. 14.
    Goss PE et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10;31(11):1398–1404Google Scholar
  15. 15.
    Goss P et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gray R et al, aTTom Collaborative Group (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31(18_suppl):5–5Google Scholar
  17. 17.
    Howell A et al, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62Google Scholar
  18. 18.
    Kaufmann M et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670. Epub 2007 June 11Google Scholar
  19. 19.
    Mamounas E et al (2006) NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 7(5):416–421CrossRefPubMedGoogle Scholar
  20. 20.
    Mamounas E et al (2016) A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42 SABCS 2016, Abstract S1–05Google Scholar
  21. 21.
    Mamounas E et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677–1683Google Scholar
  22. 22.
    Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMedGoogle Scholar
  24. 24.
    Paik S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734CrossRefPubMedGoogle Scholar
  25. 25.
    Province et al (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95(2):216–227CrossRefPubMedGoogle Scholar
  26. 26.
    Ribeiro G et al (1992) Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65(2):252CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sgroi D et al (2016) Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Res 18:1CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sparano J et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.University of Wisconsin Carbone Cancer CenterMadisonUSA

Personalised recommendations